HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

8 New FDA-Approved Neurology Drugs

The FDA has recently approved a number of drugs for a variety of neurologic disorders, including Parkinson's disease and MS. Here are 8 of the newest.

In the last year, the FDA has approved a number of drugs for a variety of neurologic disorders. Here are 8 of the most recent.

slideshow image

Bexsero (meningococcal group B vaccine) prevents invasive meningococcal disease caused by Neisseria meningitidis serogroup B in people 10 - 25 years old. The FDA approved the first meningococcal serogroup B vaccine in October 2014.Approved 1/15. Manufacturer, Novartis Vaccines and Diagnostics Inc.

slideshow image

Duopa (carbidopa and levodopa) is an aromatic amino acid decarboxylation inhibitor and aromatic amino acid combination formulated as an enteral suspension for treatment of motor fluctuations in patients with advanced Parkinson’s disease. DUOPA is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube.Approved 1/15. Manufacturer, AbbVie Inc.

slideshow image

Rytary is an extended-release oral capsule formulation of carbidopa-levodopa used in Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and /or manganese intoxication. It is not intended for use by patients taking MAO inhibitors.Approved 1/7/15; Manufacturer, Impax Pharmaceuticals

slideshow image

Dyloject (diclofenac sodium injection) is an intravenous non-steroidal anti-inflammatory drug (NSAID) for adults with mild to moderate pain and for management of moderate to severe pain alone or in combination with opioid analgesics. Approved 12/14. Manufacturer, Javelin Pharmaceuticals, Inc.

slideshow image

Namzaric is a fixed-dose combination of memantine HCL extended-release (an NMDA receptor antagonist) and donepezil HCL, an acetylcholinesterase inhibitor. Indicated for moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine HCL and donepezil HCL. Approved 12/14. Manufacturer, Adamas Pharmaceuticals Inc.

slideshow image

Lemtrada (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of patients with relapsing forms of MS. Use is generally reserved for patients who have had an inadequate response to 2 or more drugs indicated for MS. Approved 11/14. Manufacturer, Genzyme.

slideshow image

Hysingla ER (hydrocodone) is a single-entity (without acetaminophen) extended-release opioid analgesic for around-the-clock management of moderate to severe chronic pain. The drug has properties that are expected to reduce abuse of the drug when chewed and then taken orally, or crushed and snorted or injected. Approved 11/14. Manufacturer, Purdue Pharma L.P.

slideshow image

Plegridy (peginterferon beta-1a) is a pegylated interferon beta indicated for treatment of relapsing forms of multiple sclerosis. The only pegylated beta interferon approved for use in RMS. Approved 8/14. Manufacturer, Biogen Idec.

PreviousNext